Science Panel Slams FDA on BPA

A scientific panel assembled by the FDA has slammed the federal agency for ignoring what it views as crucial evidence in the ongoing debate over bisphenol-A, also known as BPA. The chemical is used in the manufacturing of hard, clear plastics and is found in nearly every clear plastic bottles including baby bottles.
The safety concerns regarding BPA are wide-ranging and vary from producing estrogen-like effects to causing cancer. In some studies, BPA has been linked to a higher risk of heart disease and diabetes as well as interfering with chemotherapy.
The scientific panel, composed of seven scientists from three major universities, the Environmental Protection Agency and the Centers for Disease Control and Prevention.
According to a story published in the New York Times, their concerns include the following:
The F.D.A. assessment does not have an adequate number of infant-formula samples and relies too heavily on averages, rather than accounting for variability in the samples.
¶The agency excluded several important animal studies that raised questions about the safety of BPA.
¶New research on BPA in adult humans and animals was published after the F.D.A.’s draft report and should be included.
¶The margins of safety for BPA exposure used by the agency are “inadequate.”